“Hairiness” is a Facsimile of Reorganized Cytoskeletons: A Cytopathic Effect of Coxiella burnetii

Won-Young Lee
Emeritus Professor, Yonsei University College of Medicine, Seoul, Korea.

INTRODUCTION

In 1993, I reported that Coxiella burnetii transforms human B cells into hairy cells (cbHCs), the first hairy cell reported outside of hairy cell leukemia (HCL). Over last few decades, advances in molecular biology have provided evidence supporting that C. burnetii induces hairiness and inhibits the apoptosis of host cells. The present review summarizes new information in support of cbHC. C. burnetii was shown to induce reorganization of the cytoskeleton and to inhibit apoptosis in host cells. Peritoneal B1a cells were found to be permissive for virulent C. burnetii Nine Mile phase I (NMI) strains in mice. C. burnetii severely impaired E-cad expression in circulating cells of Q fever patients. B-cell non-Hodgkin lymphoma was linked to C. burnetii. Mutation of BRAF V600E was pronounced in HCL, but "hairiness" was not linked to the mutation. Risk factors shared among coxiellosis and HCL in humans and animals were reported in patients with Q-fever. Accordingly, I propose that C. burnetii induces reorganization of the cytoskeleton and inhibits apoptosis as cyopathic effects that are not target cell specific. The observed hairiness in cbHC appears to be a fixed image of dynamic nature, and hairy cells in HCL are distinct among lymphoid cells in circulation. As the cytoskeleton plays key roles in maintaining cell structural integrity in health and disease, the pathophysiology of similar cyopathic effects should be addressed in other diseases, such as myopathies, B-cell dyscrasias, and autoimmune syndromes.

Key Words: Coxiella burnetii, C. burnetii-induced hairy cell, cytoskeleton, anti-apoptosis, hairy cell leukemia

HCL CHARACTERIZED BY CELLS WITH REORGANIZED CYTOSKELETONS

“Hairy cell” is a descriptive name proposed by Schrek and Donnelly in 1966.8 To date, HC has remained a diagnostic marker for HCL and variant HCL. The hairiness of cells has been also signified in variants of HCL lacking CD25, CD123,
ANXA1, TRAP, and BRAF V600E expression.9 HC owes its name to the presence of numerous irregular projections protruding from the surface of cells, which are clearly visible in a phase contrast microscope and appear as irregular undulating ruffles or long villi when examined by a scanning electron microscope.10 HCL cells are able to cap surface immunoglobulins and concanavalin A receptors; the membrane redistribution of these structures is inhibited by cytochalasin B.11,12 Cytochalasin B inhibits both the rate of actin polymerization and the interaction of actin filaments in solution. HCL cells become firmly attached to culture dish surfaces and exhibit fibroblast-like projections and stellate features.13,14 Compared with normal B cells and other lymphomas, HCL specifically overexpresses β-actin (a non-muscle cytoskeletal isoform of actin).13,14

Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia, and F-actin was predominantly associated with dot-shaped structures scattered over the ventral membrane, representing spotty close contact adhesion sites analogous to “podosomes” described in other cell types.15 In HCL cells, polymerized actin (F-actin) is primarily found in the cortical cytoskeleton and supports the filamentous (F) membrane projections of HCL cells, whereas in normal B cells and in B-cell chronic lymphocytic leukemia...
cells, F-actin is primarily located in the central part of the cell. Thus, HCL cells apparently need to increase the expression levels of actin, concentrating it at the cell periphery, to sustain their prominent membrane projections.

**HAIRINESS OF HCL IS IRRELEVANT TO BRAF-V600E MUTATION**

In 2011, BRAF V600E mutation was observed in 100% of HCLs investigated. Since that observation was published, other groups have confirmed this result, establishing the paradigm.

---

**Fig. 2.** Transmission electron microscopy (TEM) of *Coxiella burnetii* transforms human B cells into hairy cells (cbHCs) with *C. burnetii* in the cytoplasm. Ultrathin sections were fixed in glutaraldehyde examined at ×3000. (A) On low magnification TEM, the cytoplasm is filled with the organisms varying in size and shape. The part of the cytoplasm boxed in with a white line is further magnified. Bar reflects 1 μm. (B) Compactness and containing endospore-like granules (arrows). Bar reflects 1 μm. (C) Double membraned organisms and multiple ribosome lamella complexes (arrow). Bar represents 1 μm. The bottom left corner inlet is a laser scanned image of a cbHC. Bar represents 10 μm. Adopted from Lee.
that BRAF V600E is the disease-defining mutation of HCL. However, a few histologically, immunohistochemically, and clinically characteristic HCLs appear to lack the BRAF V600E mutation. These includes the variant HCLs, splenic diffuse red pulp lymphoma and splenic marginal zone lymphoma. 

HCL cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lacking the signature BRAF mutation have also been reported: Although ANXA1 expression and other phenotypic markers together with cellular behavior showed some similarities with features typical of HCL in four cell lines (HCL 7876, Eskol, HC-1, and Hair-M), the absence of BRAF mutation placed into question their reliability as representative of this form of the malignancy. 

BRAF-V600E was also investigated in the human HCL cell lines BONNA-12, ESKOL, HAIR-M, and HC-1, but none of them carried BRAF-V600E mutation. 

BRAFV600E mutation occurring as early as in hematopoietic stem and progenitor B cells was reported in patients with HCL. In one study, BRAF600E-mutant hematopoietic stem cells (HSCs) were transplanted into immunodeficient mice, and stable engraftment of BRAFV600E-mutant HSCs was verified. However, cells with classic HC-like morphology were not seen in the murine models. 

Since all animal procedures were conducted in accordance with the guidelines for the care and use of laboratory animals, the mice were immune deficient and free of pathogens, including C. burnetii. The hairless morphology of engrafted BRAFV600E-mutant HSCs in germ-free mice may have been due to the absence of C. burnetii to induce cbHC. The same explanations are applicable for research with cultured cells in media containing various antibiotics. To evaluate any results observed in cell lines established ex vivo, an extra consideration is recommended, as significant differences in chromosome ploidy and in tumorigenicity between cells in glass (i.e., in vitro) and cells in plastic (i.e., in plastic) have been demonstrated. 

Also, cell lines established ex vivo may not represent their histologic origins. Moreover, BRAF is a serine/threonine kinase that is commonly activated by somatic point mutations in human cancer, such as malignant melanoma and other solid tumors not specified by their hairy morphology. Presumptive BRAF mutations are found in normal tissue DNAs, cancer cell lines, colorectal cancers, gliomas, cancers, sarcomas, ovarian carcinomas, breast cancers and liver cancers. Thus, BRAF appears to be unrelrated to the hairiness of cells, and stemness of BRAF mutants may not be specific to a certain disease.

C. burnetii AND ROUTE OF INFECTION

Most human infections occur after inhalation of infected aerosols of C. burnetii, and anecdotal cases of human-to-human transmission through infected aerosols have been reported after autopsies. Ticks may play a role in the transmission of C. burnetii infection. This is illustrated by the detection of C. burnetii coinfection with other arthropod-borne pathogens in ticks. Q fever pneumonia is considered a nosocomial disease, and a recent case of respiratory nosocomial spread was reported. Because C. burnetii may persist for prolonged periods in the soil, these aerosols may also be produced long after the release of bacteria by infected animals. Moreover, bacterial aerosols can travel at least 30 km by the wind, resulting in Q fever cases far away from the primary source of contamination. Thus, Q fever cases are often diagnosed in persons with no recent contact with animals.

Birth products from infected parturient women are also a source of infection in obstetrical wards. A case of C. burnetii pneumonia was diagnosed by an obstetrician 7 days after he delivered an infant of an infected woman. Also, nosocomial transmission between two pregnant women sharing the same room has been reported. In these cases, the most probable source of the infection was infected, aerosolized vaginal excretion particles. C. burnetii infection through transfusion of blood collected from Q fever patients with bacteremia is also plausible, since the bacterium can survive in stored human blood samples.

REORGANIZATION OF THE CYTOSKELETON BY C. burnetii

Many bacterial pathogens accomplish reorganization of the cytoskeleton by employing an arsenal of highly sophisticated mechanisms that subvert the cellular actin cytoskeleton to trigger their internalization into normally nonphagocytic host cells in order to escape the humoral immune defense. Among the multiple regulation steps of the actin cytoskeleton, bacterial factors interact preferentially with Rho GTPases. 

Reports of C. burnetii-induced morphologic changes in infected cells support the results of cbHC studies. Cytochalasin D, an inhibitor of actin polymerization, was found to prevent the uptake of C. burnetii without interfering with its binding. Thus, bacterial adherence may be necessary for tumor necrosis factor (TNF) production by monocytes. The monocyte αβ3 integrin was shown to be involved in TNF synthesis, and interestingly, peptides containing arginine-glycine-aspartic acid sequences and blocking antibodies against αβ3 integrin inhibited TNF transcripts induced by C. burnetii. Although both phase I and phase II variants engage αβ3 integrin receptor in monocytes, dramatic reorganization of the F-actin cytoskeleton was observed with phase I bacteria. In human myelomonocytic cells infected with virulent C. burnetii, a profound polymorphic change in cells was reported.
Differences in actin cytoskeleton reorganization according to the virulence of the infecting organism has been demonstrated, with virulent organisms showing lower reorganization than avirulent variants. In peripheral blood lymphocyte cultures infected with *C. burnetii*, exclusive pseudopodal extension and polarized distribution of F-actin were observed. Moreover, reorganization of the actin cytoskeleton by *C. burnetii* was reported to play a critical role in the internalization strategy of the organism, which is known to replicate exclusively within viable eukaryotic cells. A role for activation of protein tyrosine kinases (PTK) by *C. burnetii* has been implicated in actin cytoskeleton reorganization and bacterial phagocytosis. The phagocytosis of particles by macrophages was shown to depend primarily on reorganization of the actin cytoskeleton underlying the region of the plasma membrane that is in contact with particles. Virulent organisms were found to induce early PTK activation and tyrosine phosphorylation of several endogenous substrates, including Hick and Lyn, two Src-related kinases. Such PTK activation reflects *C. burnetii* virulence, since avirulent variants were unable to stimulate PTK. Actin cytoskeletal ruffling induced via Src tyrosine kinases was observed following the binding of phase I *C. burnetii*. This membrane ruffling required contact between *C. burnetii* and host cells and could be induced using purified lipopolysaccharide (LPS) from phase I bacteria.

The ability to induce these ruffles appears to be dependent on the expression of Toll-like receptor 4 (TLR4) on the host cell surface. These observations suggest that LPS induces membrane ruffling and a type IV secretion system (T4SS) that temporally controls downstream signaling cascades after internalization. In animals, after aerosol transmission, *C. burnetii* targets alveolar macrophages and passively enters these cells. Infection of phase I *C. burnetii* indicated that this bacterium uses an active triggering mechanism (mediated by the secretion of T4SS effector proteins) to induce uptake after initial binding to the host cell. Although the T4SS of *C. burnetii* is not required for uptake by the host cell, it remains to be determined whether T4SS effectors contribute to the reorganization of the actin cytoskeleton during infection.

Detailed molecular mechanisms are lacking due to difficulty in genetically manipulating these bacteria. Nevertheless, recent genetic breakthroughs have provided controllable systems by which bacteria-actin interactions can now be defined for this intriguing group of pathogens.

In 2019, it was reported that *C. burnetii* affects E-cadherin (E-cad) expression. Researchers showed that *C. burnetii* severely impaired E-cad expression in circulating cells of Q fever patients. Cadherin switching is known to be a hallmark of neoplastic processes.

In summation, these discoveries validate that *C. burnetii* reorganize the cytoskeletons of host cells, leading to the hairy appearance observed in cbHCs. Thus, cytoskeleton reorganization appears to be a *C. burnetii*-specific cytopathic effect that is not target specific.

Nature of HCL is B cell and peritoneal B1a cells were found to be permissive for virulent *C. burnetii* (Nine Mile phase I) strains in mice. *C. burnetii* infection B1a cells play an important role in regulating the *C. burnetii* infection-induced inflammatory response.

**INHIBITION OF APOPTOSIS BY *C. burnetii***

Eukaryotic cells often respond to intracellular pathogen invasion and stress induction by initiating the intrinsic apoptotic pathway as part of the innate immune defense. Two main pathways lead to apoptosis: the extrinsic cell death pathway is launched in response to stimulation of death receptor proteins at the cell surface by extracellular stimuli, while the intrinsic cell death pathway is initiated in response to intracellular stimuli. Apoptosis allows for pathogen clearance without inflammation and additionally leads to activation of the adaptive immune defense.

As a countermeasure, intracellular pathogens have developed multiple mechanisms to inhibit host cell apoptosis. In 2009, researchers developed a means with which to axenically culture bacteria. These advances have provided the capacity to examine the pathogenesis of *C. burnetii*. More than a few studies have established that *C. burnetii* actively inhibits host cell death machinery by preventing the activation of both the intrinsic, mediated by mitochondria, and extrinsic, death receptor-mediated, apoptotic pathways. In particular, inhibition of cytochrome c release from mitochondria and continuous activation of the pro-survival kinases Akt and Erk1/2 have been observed during *Coxiella* infection.

One of the first *C. burnetii* effectors to be identified, AnkG, was shown to inhibit apoptosis on a physiologically relevant scale. Further study revealed that AnkG interacts with the host mitochondrial protein p32 and that this interaction is important for transporting AnkG to the nucleus where it exerts an anti-apoptotic phenotype.

Screening of previously identified *C. burnetii* effectors for the capacity to inhibit intrinsic apoptosis revealed two more anti-apoptotic effectors, CBU1524 and CBU1532, renamed CaeA and CaeB (*C. burnetii* anti-apoptotic effectors). The discovery of three independent anti-apoptotic effectors indicates some functional redundancy; however, AnkG, CaeA and CaeB possess distinct mechanisms to block apoptosis and therefore may all contribute to the strong anti-apoptotic properties of *Coxiella*-infected cells. These studies, however, only screened a small proportion of known *Coxiella* effectors, and it is plausible that several more effectors contribute to maintaining host viability. Moreover, the data demonstrating the anti-apoptotic function of AnkG, CaeA and CaeB were not in the context of...
Coxiella infection. As such, it still remains to be determined whether the absence of these effectors, individually or in combination, impacts host cell survival during infection and the subsequent ability of Coxiiella to replicate.

In 2019, Melenotte, et al.\textsuperscript{68} found the over-expression of genes involved in anti-apoptotic process and repression of pro-apoptotic genes as compared to samples from healthy donors by analyzing their gene expression by microarray.

COMPARABLE RISK FACTORS FOR COXIELLOSIS AND HCL

In HCL, an increased risk of the disease from farming exposure and a decreased risk from smoking exposure has been observed in studies independent of one another.\textsuperscript{69-71} Physicians practicing in rural areas should consider *C. burnetii* infection when patients present with atypical pneumonia and suggestive risk factors.\textsuperscript{72}

SUMMARIZING REMARKS

*C. burnetii* reorganize the cytoskeleton and inhibits apoptosis of host cell. I propose these are *C. burnetii* induced cytopathic effects that are not target specific. Incidentally, a case of T-cell acute lymphoblastic leukemia with cells with unusual hairy projections was reported.\textsuperscript{73} Herein, *C. burnetii* infection of the patients should be considered.

ORCID ID

Won-Young Lee  https://orcid.org/0000-0002-0222-4572

REFERENCES

1. Lee WY. Hairy cell transformation of human peripheral blood lymphocytes by Coxiiella burnetii. Jpn J Med 1993;34:11-21.
2. Lee WY, Lee JM, Park KH, Park C, Chang M, Hong WP, et al. Coxiiella burnetii in polymorphic lymphocytes in tissue and blood of patients with polymorphic reticulosis. Acta Virol 1995;39:269-74.
3. Angelakis E, Raoult D. Q fever. Vet Microbiol 2010;140:297-309.
4. Melenotte C, Million M, Audoly G, Gorse A, Dutronc H, Toussof M, et al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Yonsei Med J 1993;34:11-21.
5. Ammatuna E, Iannitto E, Tick LW, Arents NL, Kuijper PH, Nijziel MT. Two cases of Q-fever in hairy cell leukemia. Case Rep Hema tol 2014;2014:863932.
6. Achten-Weiler M, Veldhuis Kroeze EJ, Boerma S, van der Kolk JH. Ultrastruct Pathol 2006;30:85-94.
7. Al-Bagdadi FK, Seger CL, Henry RW, Neal Maulden G. Acute lymphoblast leukemia in sheep induced by inoculation of bovine leukemia virus: diagnostic electron microscopic morphological study. Ultrastruct Pathol 2006;30:85-94.
8. Shorr R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood 1966;27:199-211.
9. Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman Rj, Stetler-Stevenson M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013;37:401-9.
10. Braylan RC, Jaffe ES, Triche TJ, Namba K, Fowlkes Bi, Metzger H, et al. Structural and functional properties of the “hairy” cells of leukemic reticuloendotheliosis. Cancer 1978;41:210-27.
11. Golomb HM, Mintz U, Vandimain J, Wilson C, Rosner MC. Surface immunoglobulins, lectin-induced cap formation, and phagocytic function in five patients with the leukemic phase of hairy cell leukemia. Cancer 1980;46:50-5.
12. Caligaris-Cappio F, Janossy G, Campana D, Chilosi M, Bergui L, Foà R, et al. Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA. Leuk Res 1984;8:567-78.
13. Braun J, Unanue ER. The lymphocyte cytoskeleton and its control of surface receptor functions. Semin Hematol 1983;20:322-33.
14. Cohen HJ. Human lymphocyte surface immunoglobulin capping. Normal characteristics and anomalous behavior of chronic lymphocytic leukemia lymphocytes. J Clin Invest 1975;55:84-93.
15. Caligaris-Cappio F, Bergui L, Tesio L, Corbascio G, Toussof M, Marchiolo PC. Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. Blood 1986;67:239-9.
16. Schrek R, Messmore HL, Knospe WH, Stefani SS. A colchicine-sensitivity test for leukemic lymphocytes. Scand J Haematol 1976;16:357-64.
17. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.
18. Achten-Weiler M, Veldhuis Kroeze EJ, Boerma S, van der Kolk JH. Ultrastruct Pathol 2006;30:85-94.
H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
29. Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999;12:518-53.
30. Tissot-Dupont H, Raoult D. Q fever. Infect Dis Clin North Am 2008; 22:505-14.
31. Parker NR, Barralet JH, Bell AM. Q fever. Lancet 2006;367:579-88.
32. Robyn MP, Newman AF, Amato M, Walawander M, Kothe C, Nerone JD, et al. Q fever outbreak among travelers to Germany who received live cell therapy—United States and Canada, 2014. MMWR Morb Mortal Wkly Rep 2015;64:1071-3.
33. Dupont HT, Brouqui F, Faugere B, Raoult D. Prevalence of antibodies to Coxiella burnetii, Rickettsia conorii, and Rickettsia typhi in seven African countries. Clin Infect Dis 1995;21:1126-33.
34. Mancini I, Di Luca M, Toma L, Vescio F, Bianchi R, Khoury C, et al. Prevalence of tick-borne pathogens in an urban park in Rome, Italy. Ann Agric Environ Med 2014;21:723-7.
35. Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. Wind in No vember, Q fever in December. Emerg Infect Dis 2004;10:1264-9.
36. Racult D, Stein A. Q fever during pregnancy--a risk for women, fetuses, and obstetricians. N Engl J Med 1984;330:371.
37. Amit S, Shinar S, Haltuz O, Atiya-Nasagi Y, Giladi M. Suspected person-to-person transmission of Q fever among hospitalized pregnant women. Clin Infect Dis 2014;58:e146-7.
38. Kersh GI, Priestley R, Massung RF. Stability of Coxiella burnetii in stored human blood. Transfusion 2013;53:1493-6.
39. Rottner K, Stradal TE, Wehland J. Bacteria-host-cell interactions at the plasma membrane: stories on actin cytoskeleton subscription. Dev Cell 2005;9:3-17.
40. Popoff MR. Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host. Small GTPases 2015;6: pii: e28209.
41. DellaCasagrande J, Ghigo E, Hammami S, Toman B, Raoult D, Capo C, et al. alpha(v)beta(3) integrin and bacterial lipopolysaccharide are involved in Coxiella burnetii-stimulated production of tumor necrosis factor by human monocytes. Infect Immun 2000; 68:5673-8.
42. Meconi S, Jacomo V, Boquet P, Raoult D, Mege JL, Capo C. Coxiella burnetii induces reorganization of the actin cytoskeleton in human monocytes. Infect Immun 1998;66:5527-33.
43. Ghigo E, Capo C, Tung CH, Raoult D, Gorvel JP, Mege JL. Coxiella burnetii survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN-gamma mediates its restoration and bacterial killing. J Immunol 2002;169:4488-95.
44. Ramaekers FC, Bosman FT. The cytoskeleton and disease. J Pathol 2004;204:351-4.
45. Meconi S, Capo C, Remacle-Bonnet M, Pommier G, Raoult D, Mege JL. Activation of protein tyrosine kinases by Coxiella burnetii: role in actin cytoskeleton reorganization and bacterial phagocytosis. Infect Immun 2001;69:2520-6.
46. Conti F, Boucherit N, Baldassarre V, Troupin V, Toman R, Mottola G, et al. Coxiella burnetii lipopolysaccharide blocks p38- and MAPK activation through the disruption of TLR-2 and TLR-4 association. Front Cell Infect Microbiol 2015;4:182.
47. Honstetter A, Ghigo E, Moynault A, Capo C, Toman R, Akira S, et al. Lipopolysaccharide from Coxiella burnetii is involved in bacterial phagocytosis, filamentous actin reorganization, and inflammatory responses through toll-like receptor 4. J Immunol 2004;172:3095-703.
48. Baca OG, Klassen DA, Aragon AS. Entry of Coxiella burnetii into host cells. Acta Virol 1993;37:143-55.
49. Seshadri R, Paulsen IT, Eisen JA, Read TD, Nelson KE, Nelson WC, et al. Complete genome sequence of the Q-fever pathogen Coxiella burnetii. Proc Natl Acad Sci U S A 2003;100:5455-60.
50. Beare PA, Gilk SD, Larson CL, Hill J, Stead CM, Omsland A, et al. Dot/lcm type IVB secretion system requirements for Coxiella burnetii growth in human macrophages. MBio 2011;2:e00175-11.
51. Carey KL, Newton HJ, Liuhrmann A, Roy CR. The Coxiella burnetii Dot/lcm system delivers a unique repertoire of type IV effectors into host cells and is required for intracellular replication. PLoS Pathog 2011;7:e1002056.
52. McDonough JA, Newton HJ, Roy CR. Coxiella burnetii secretion systems. In: Toman R, Heinzen RA, Samuel JE, Mege JL, editors. Coxiella burnetii: recent advances and new perspectives in research of the Q fever bacterium. Dordrecht: Springer; 2012. p.171-97.
53. Mezouar S, Omar Osman I, Melenotte C, Slimani C, Chartier C, Raoult D, et al. High concentrations of serum soluble E-cadherin in patients with Q fever. Front Cell Infect Microbiol 2019;9:219.
54. Schoenlaub L, Elliott A, Frecches D, Mitchell WJ, Zhang G. Role of B cells in host defense against primary Coxiella burnetii infection. Infect Immun 2015;83:4826-36.
55. Lamkanfi M, DIXIT VM. Manipulation of host cell death pathways during microbial infections. Cell Host Microbe 2010;8:44-54.
56. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570-83.
57. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endoge nous activators of dendritic cells. Nat Med 1999;5:1249-55.
58. Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications in health and disease. J Cell Biol 2010;189:1059-70.
59. Faherty CS, Maurelli AT. Staying alive: bacterial inhibition of apoptosis during infection. Trends Microbiol 2008;16:173-80.
60. Omsland A, Cockrell DC, Howe D, Fischer ER, Virtaneva K, Sturdevant DE, et al. Host cell-free growth of the Q fever bacterium Coxiella burnetii. Proc Natl Acad Sci U S A 2009;106:4430-4.
61. Liuhrmann A, Roy CR. Coxiella burnetii inhibits activation of host cell apoptosis through a mechanism that involves preventing cytochrome c release from mitochondria. Infect Immun 2007;75: 5282-9.
62. Voth DE, Heinen RA. Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii. Cell Microbiol 2007;9:829-40.
63. Voth DE, Heinen RA. Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity. Infect Immun 2009;77:205-13.
64. Pan X, Liuhrmann A, Satoth A, Laskowski-Arce MA, Roy CR. Ankyrin repeat proteins comprise a diverse family of bacterial type IV effectors. Science 2008;320:1651-4.
65. Liuhrmann A, Nogueira CV, Carey KL, Roy CR. Inhibition of pathogen-induced apoptosis by a Coxiella burnetii type IV effector protein. Proc Natl Acad Sci U S A 2010;107:18997-9001.
66. Eckart RA, Bisle S, Schulze-Luehrmann J, Wittmann I, Jantsch I, Schmid B, et al. Antiapoptotic activity of Coxiella burnetii effector protein AnkG is controlled by p32-dependent trafficking. Infect Immun 2014;82:2763-71.
67. Klingenbeck L, Eckart RA, Berens C, Liuhrmann A. The Coxiella burnetii type IV secretion system substrate CaeB inhibits intrinsic apoptosis at the mitochondrial level. Cell Microbiol 2013;15: 675-87.
68. Melenotte C, Mezouar S, Ben Amara A, Benatti S, Chiaroni J, Devaux C, et al. A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever. PLoS One 2019;14:e0217542.
69. Monnerau E, Slager SL, Hughes AM, Smith A, Glimelius B, Habermann TM, et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014:115-24.
70. Tadmor T, Polliaec A. Epidemiology and environmental risk in hairy
cell leukemia. Best Pract Res Clin Haematol 2015;28:175-9.
71. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CE et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:130-44.
72. Meadows S, Jones-Bitton A, McEwen SA, Jansen J, Patel SN, Filejski C, et al. Coxiella burnetii (Q Fever) seropositivity and associated risk factors in sheep and goat farm workers in Ontario, Canada. Vector Borne Zoonotic Dis 2016;16:643-9.
73. Somasundaram V, Ahuja A, Manivannan P, Chandra D, Purohit A, Saxena R. Unusual hairy projections in a case of T-acute lymphoblastic leukemia, a cause for diagnostic dilemma: a case report. J Hematol Thrombo Dis 2015;3:223.